Project Grant F31CA314096
Award Date 12/10/26
Completion Date 6/28/28
Dollars Obligated $102K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded the Regents of the University of Minnesota $650,590 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate properties of T cell receptors that govern pancreatic cancer immunotherapy response. The funded research investigates how T cells function within the pancreatic tumor microenvironment and respond to immunotherapy, with a focus on T cell receptor (TCR) features...
- The National Cancer Institute awarded the Regents of the University of Minnesota $573,262 on April 17, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop autologous humanized leukemia models for immunotherapy testing. The recipient will generate patient-derived xenograft models using paired leukemia and immune cells from the same pre-B acute lymphoblastic leukemia patient, addressing a gap in preclinical testing where current models either lack functional immune systems...
- The National Cancer Institute awarded $107,871 to the Regents of the University of Minnesota on January 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support development of a dual-antigen natural killer cell engager platform targeting ovarian cancer tumor heterogeneity. The funded research develops a tri-specific killer engager (TRIKE) combined with a poly-antigen cytokine complex (PACC) designed to enhance NK cell activity by simultaneously targeting CD16 on NK cells,...
- The National Cancer Institute awarded the Regents of the University of Minnesota $406,325 on May 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop CRISPRMAP-CYTOF, a single-cell screening platform that integrates high-complexity pooled CRISPR perturbations with mass cytometry-based protein-level profiling. The platform combines the CRISPRMAP combinatorial barcoding strategy with photocrosslinking-based DNA stabilization to simultaneously decode thousands of gene...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $395,973 to the Regents of the University of Minnesota on July 21, 2026, under the Cancer Biology Research program (CFDA 93.396, assistance type: Project Grant). The award funds research into epitranscriptomic regulation of PAX3-FOXO1 and PAX7-FOXO1 fusion genes in alveolar rhabdomyosarcoma, a pediatric soft tissue sarcoma resistant to current therapies. The investigator's...
- The National Cancer Institute awarded Gigamune Inc. $800,000 on September 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop a novel lentivector for enhanced in vivo delivery of T cell receptors for cell therapy targeting stage IV melanoma. The research project, titled "A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma" and led by principal investigator David Scott Johnson, Ph.D., aims to create an...
- The National Cancer Institute awarded the Regents of the University of Minnesota $309,761 on May 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and deliver a hands-on training course in biomarker development and applications for cancer prevention research. The course combines virtual modules on chemical carcinogenesis fundamentals with five weeks of in-person laboratory training in state-of-the-art biomarker measurement techniques at the Masonic Cancer Center....